News
Australian sleep health giant Resmed has locked down an exemption from Donald Trump’s sweeping trade tariffs. Resmed produces ...
EPS of $2.37 on $1.29 billion in sales, citing strong global demand for sleep devices, plus a boost from tariff exemptions.
A major Australian company has managed to secure a tariff exemption from the Trump Administration as the world waits to see ...
Noise level: Our pick for the best quiet CPAP machine is the Luna G3, but you'll want to make sure that whichever model you ...
KeyBanc analyst Brett Fishbin raised the firm’s price target on ResMed (RMD) to $274 from $269 on higher estimates, while keeping an Overweight ...
Resmed shares remained unmoved after hours today on third-quarter results that came in ahead of the consensus forecast.
ResMed Inc (RMD) reports an 8% revenue increase and plans to boost share buybacks, while navigating global trade challenges ...
RBC Capital raised the firm’s price target on ResMed (RMD) to $255 from $247 and keeps a Sector Perform rating on the shares. The company’s Q3 ...
Resmed reported third quarter 2025 revenues of $1.3 billion, an increase of 8% over the same quarter the prior year.
Resmed beat Wall Street estimates for third-quarter profit on Wednesday, driven by demand for its sleep apnea devices used to manage the common sleep disorder. The company manufactures continuous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback